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Summary The mean total serum oestradiol level was found to be significantly increased in 8 male patients
with carcinoma of the breast when compared with 8 healthy reference subjects matched for race, sex and age.
The calculated mean free oestradiol index was also higher in these patients. There were no significant
differences, however, between the levels of LH, FSH, prolactin, DHEA-S, testosterone and SHGB in the 2
groups. The patients showed a significantly increased LH response to GnRH while there was no difference in
the FSH response. Only 1/7 patients had a tumour devoid of steroid hormone receptors. It may be that an
increased level of circulating oestradiol-17,B is an important factor in the aetiology of hormone-dependent
male breast cancer.
Whereas the clinical course and pathological
features of carcinoma of the male breast are similar
to those in the female, the average incidence is
generally reported to be - 1% of all mammary
cancers. Amongst Black and Asian South Africans,
the frequency of male breast cancer is not known,
but over a 9-year period at King Edward VIII
Hospital, Durban, 3.0% of Black patients who
presented with carcinoma of the breast, were male.
In the same period, 1.8% of Asian patients were
men. A figure of 2.4% has been recorded amongst
a West African hospital population (Ajayi et al.,
1982), while a report from Zambia claims an
incidence of 15% (Bhagwandeen, 1972). No
satisfactory explanation for the increased incidence
amongst Blacks has yet been found.
Carcinoma of the male breast is today recognised
as being, for the most part, a hormone-dependent
malignancy. A high proportion of tumours contain
steroid hormone receptors. We have demonstrated
cytoplasmic oestrogen receptors (REc) in 16/17
(94%) male breast cancers, 13 of these patients
having been discussed previously (Pegoraro et al.,
1982), while a survey of the literature revealed that
88/103 (85%) tumours were positive for REC
(Everson et al., 1980; Ruff et al., 1981; Pegoraro et
al., 1982). In 1942 Farrow and Adair achieved a
regression in a patient with inoperable breast
cancer, following bilateral orchidectomy and, since
then, it has been reported that between 50 and 70%
of patients with advanced male breast cancer
respond to endocrine ablative surgery or hormonal
therapy (Treves, 1959; Neifeld et al., 1976) and,
more recently, to tamoxifen (Patterson et al., 1980).
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The rationale behind this success has become
clearer with reports of increased levels of urinary
and plasma oestrogens in male patients with breast
cancer (Dao et al., 1973; Calabresi et al., 1976).
As a result of these findings and the fact that for
many years there has been speculation on a possible
hormonal role in the aetiology of male breast
cancer (Scheike, 1976), the endocrine profile of
male patients with carcinoma of the breast has been
examined and related to the steroid hormone
receptor status.
Materials and methods
Patients and reference subjects
The study group comprised 8 consecutive male
patients (7 Blacks, 1 Asian) presenting during the
period December 1981 to March 1983, and 8
healthy reference subjects matched for age, sex and
race. All patients had histologically proven ductal
carcinoma of the breast, 7 were invasive and one in
situ (Patient 6, Table III).
Patients were questioned regarding previous
trauma to the testes, orchitis and exposure to
exogenous hormones, and clinical examination was
directed to detection of sex hormone-associated
abnormalities, particularly gynaecomastia and
Klinefelter's syndrome. In addition to the hormone
studies described below, blood was withdrawn for
karotyping, estimation of serum creatinine and tests
of liver function which included the plasma proteins
(albumin and globulin), bilirubin and plasma
enzymes (alkaline phosphatase, y-glutamyl
transpeptidase, aspartate transaminase and lactate
dehydrogenase). These were estimated by standard
automated laboratory techniques, while
karyotyping was performed by the method of
Defendi et al. (1960).
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Endocrine studies
Fasting blood samples were taken for luteinising
hormone (LH), follicle stimulating hormone (FSH),
prolactin, dehydroepiandrosterone-sulphate
(DHEA-S), oestradiol-17p, testosterone and sex
hormone binding globulin (SHBG). The hormone
levels were measured by radioimmunoassay, using
commercially available kits: LH (Diagnostic
Products Corporation, California), FSH
(Amersham, UK), prolactin (Serono Diagnostics,
Switzerland), DHEA-S (Radioassay Systems
Laboratories, California), oestradiol-17,B (Radio
Isotopen Service, Schweiz) and testosterone
(Immunochemical Corporation, California). SHBG
levels were quantitated by saturation analysis
according to Rudd et al. (1974). The free oestradiol
index and free testosterone index were calculated as
follows:
total oestradiol or testosterone (pmol1-1)
SHBG (pmoll-1).
The intra- and interassay coefficients of variation
for all assays were <10%.
Dynamic endocrine tests
Five patients and 5 reference subjects were fasted
overnight before blood samples were drawn for LH
and FSH via an indwelling cannula inserted 30min
previously. Thereafter, 0.1 mg gonadotrophin
releasing hormone (GnRH) was injected i.v. and
further samples were taken at 20 and 60min.
Statistical analyses
Data are expressed as mean and standard error,
and the ranges shown. Differences in hormone
levels between the patients and reference subjects
were analysed by the Mann-Whitney U Test and
were considered significant when P<0.02.
Hormone receptor studies
Breast tumour or lymph node tissue for steroid
hormone receptor assays was obtained from the
patients either at mastectomy or by biopsy.
The assay methods used have been described in
detail previously (Pegoraro et al., 1980, 1982).
Briefly, cytoplasmic oestrogen (REJ) and
cytoplasmic progesterone receptors (RP,) were
estimated by means of multipoint, dextran-coated
charcoal assays; nuclear oestrogen (RE.) and
nuclear progesterone receptors (RPn) were
measured in a nuclear suspension and separation of
bound from free radioactive ligand was effected on
Whatman GF/C filters using a Millipore filtration
unit.
Results
Clinicalfindings
The history and examination of the patients did not
reveal any evidence of orchitis, previous trauma to
the testes, exposure to exogenous oestrogens or
signs of sex hormone-related abnormalities, notably
gynaecomastia and Klinefelter's syndrome.
Laboratoryfindings
Klinefelter's syndrome was also excluded on the
grounds of normal XY karyotyping. Serum
creatinine levels and tests of liver function were
normal except in one patient who had raised serum
alkaline phosphatase levels. This patient had
multiple osseous metastases.
Hormone levels
The mean fasting levels and ranges of LH, FSH,
prolactin, DHEA-S and SHBG in the 8 patients
with breast carcinoma and the 8 matched reference
subjects, are shown in Table I. There were no
significant differences in these hormone levels
between the 2 groups.
The mean total serum oestradiol-17f level,
however, was significantly increased in the patients
with breast cancer as was the calculated mean free
oestradiol index (Table I). Both the mean total
testosterone and the calculated mean free
testosterone index were slightly higher in the
patients, but these levels remained within the
reference ranges for normal males.
In response to GnRH, the LH levels at 20 and
60min were significantly higher in the breast cancer
patients, while there was no significant difference in
the FSH responses between the two groups (Table
II).
Hormone receptor levels
Oestrogen and progesterone receptor values are
shown in Table III. No significant relationship
could be found between REC values and the total
oestradiol levels (r= -0.2058; P>0.1) or the free
oestradiol index (r -0.2214; P>0.1), using linear
regression analysis.
Discussion
This study has demonstrated significantly increased
mean total serum oestradiol-17f levels in patients
with male breast cancer when compared with
reference subjects, a finding which supports
Calabresi et al. (1976), who reported increasedHORMONES IN MALE BREAST CANCER 425
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Table II Mean (±s.e.) LH and FSH responses to GnRH
in 5 patients with male breast cancer and 5 reference
subjects
0 min 20 min 60 min
LH (mIUml)
Patients 7.8 (1.3) 67.3 (12.1) 56.4 (6.5)
* P<0.01 P<0.01
Reference
subjects 6.6 (1.2) 27.8 (4.7) 28.2 (3.8)
FSH (mIUml-')
Patients 8.6 (2.3) 14.7 (3.7) 13.9 (2.5)
* * *
Reference
subjects 7.2 (1.5) 10.2 (2.1) 12.8 (1.7)
*(P>0.02).
plasma oestrone, oestradiol and oestriol in male
patients with breast carcinoma.
The most striking feature of the study, however,
is the significantly increased mean free oestradiol
index found in the patients. Although the calculated
index of free steroid does not represent an absolute
measure of the free hormone, it is indicative of the
free form of the steroid (Anderson, 1976). In
addition, since the SHBG levels were similar in
patients and reference subjects, the increased total
oestradiol levels may be seen as a reflection of the
free or active form of the steroid. Further evidence
for increased free oestradiol was seen by the
significantly greater LH response to GnRH in the
patients. In females the increase in oestradiol prior
to ovulation is known to exert a positive effect on
the LH response to GnRH (Odell, 1979). Despite
these increased levels of free oestradiol-17p, the
relative increase appeared, however, to be
insufficient to have resulted in gynaecomastia in
these patients or in any increase in the SHBG
levels.
Although prolactin has been suggested to play a
role in breast cancer (Smithline et al., 1975), it was
not found to be elevated, and neither were the
basal serum pituitary gonadotrophins different in
the patients and reference group. Urinary
gonadotrophins were not measured in this study,
but Scheike (1976) found significantly lower urinary
excretion of gonadotrophins in 25 males with breast
cancer.
The tumours of 7 patients in this study were
examined for steroid hormone receptors. No
relationship between receptor concentrations and
oestradiol levels was found, although it was
interesting to note that the one patient whose
tumour was completely devoid of receptors (Patient
1), was also the only patient to have an oestradiol-
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Table III Oestradiol levels and steroid receptor status in patients with male breast cancer
REk RE, RP, RPn
Total E2 Free E2 in- (fmolmg1 (fmolmg1 (fmolmg' (fmolmg
(pmoll-1) dex (x 10-3) protein) DNA) protein) DNA)
Patient Age
1 25 71.9 1.28 0 0 0 0
2 75 320.1 3.44 103 1288 3231 6656
3 56 480.2 5.52 49 1167 0 0
4 77 167.8 1.97 239 1220 519 0
5 65 131.4 2.43 274 1063 451 1835
6 64 240.5 4.45 tumour unsuitable for assay
7 39 204.8 3.20 15 286 21 0
8 54 164.7 2.42 77 490 0 0
17, level which fell within the reference range for
normal males. It may be that hormone
unresponsive male breast cancer has an aetiology
which differs from that of hormone dependent
breast cancer and that increased levels ofcirculating
oestradiol-17,B are an important factor in the
development and growth of hormone dependent
tumours. Support for a role for steroids has been
shown in animal experiments in which mammary
tumours, containing both oestrogen and
progesterone receptors, have been induced in male
rats following oestrogen and progesterone
administration (Hannouche et al., 1982).
Despite the higher percentage of males with
breast carcinoma in Africa, no abnormalities
specific to patients in this study have been
identified to account for the higher incidence. While
this study has confirmed the finding of increased
total oestradiol-17fl levels in male breast cancer
and has shown this to be due to an increase in the
free form of the steroid, the exact source of this
oestradiol remains unclear. Clinical testicular
abnormalities were absent as was any evidence of
abnormal liver function. Measurement of the
sulphate of the adrenal oestradiol intermediate
DHEA, in 4 of the patients in this study, showed
no difference from that of the reference subjects
and, therefore, it seems unlikely that the increased
oestradiol levels were originating from the adrenal
gland. It would appear then that the biochemical
lesion in the majority of male breast cancers lies is
the testes. A very effective form of therapy in male
breast carcinoma is orchidectomy and Calabresi et
al. (1976) have shown dramatic decreases in the
levels of both oestradiol-17,B and testosterone
following castration. Whether the increase in serum
oestradiol in breast cancer patients is due to
testicular secretion of oestradiol-17,B per se, or is
the result of an increased rate of peripheral
transformation of androgen precursors, is not
known at this stage.
This study was supported by the South African Medical
Research Council through the Preclinical Diagnostic
Chemistry Research Group.
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